Bactericidal Activities of HMR 3647, Moxifloxacin, and Rifapentine Against Mycobacterium Leprae in Mice

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Sep 19

PMID 10991891

Citations 14

Authors

S Consigny

A Bentoucha

P Bonnafous

J Grosset

B Ji

Affiliations

Soon will be listed here.

Abstract

Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP). Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10 mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slightly more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae.

Citing Articles

Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.

Lenz S, Collins J, Ray N, Hagge D, Lahiri R, Adams L PLoS Negl Trop Dis. 2020; 14(9):e0008583.

PMID: 32936818 PMC: 7494095. DOI: 10.1371/journal.pntd.0008583.

An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.

Mieras L, Taal A, van Brakel W, Cambau E, Saunderson P, Smith W BMC Infect Dis. 2018; 18(1):506.

PMID: 30290790 PMC: 6173927. DOI: 10.1186/s12879-018-3402-4.

Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

da Silva Cruz R, Buhrer-Sekula S, Penna M, Penna G, Talhari S An Bras Dermatol. 2018; 92(6):761-773.

PMID: 29364430 PMC: 5786388. DOI: 10.1590/abd1806-4841.20176724.

Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study.

Sarathi Mohanty P, Naaz F, Bansal A, Gupta U Mol Biol Res Commun. 2017; 6(3):113-122.

PMID: 29071280 PMC: 5640893. DOI: 10.22099/mbrc.2017.4084.

Nitazoxanide is active against Mycobacterium leprae.

Bailey M, Na H, Duthie M, Gillis T, Lahiri R, Parish T PLoS One. 2017; 12(8):e0184107.

PMID: 28850614 PMC: 5574600. DOI: 10.1371/journal.pone.0184107.

References

. Global leprosy situation, September 1999. Wkly Epidemiol Rec. 2001; 74(38):313-6. View

Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J . In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998; 42(8):2066-9. PMC: 105862. DOI: 10.1128/AAC.42.8.2066. View

Colston M, Hilson G, Banerjee D . The "proportional bactericidal test": a method for assessing bactericidal activity in drugs against Mycobacterium leprae in mice. Lepr Rev. 1978; 49(1):7-15. View

SHEPARD C . Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int J Lepr Other Mycobact Dis. 1982; 50(1):96-101. View

. Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser. 1982; 675:1-33. View

Ji B, Chen J, Lu X, Wang S, Ni G, Hou Y . Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473. Int J Lepr Other Mycobact Dis. 1986; 54(4):563-77. View

GELBER R . Activity of minocycline in Mycobacterium leprae-infected mice. J Infect Dis. 1987; 156(1):236-9. DOI: 10.1093/infdis/156.1.236. View

Ellard G, Pannikar V, Jesudasan K, Christian M . Clofazimine and dapsone compliance in leprosy. Lepr Rev. 1988; 59(3):205-13. DOI: 10.5935/0305-7518.19880026. View

Grosset J, Ji B, Perani E, NDeli L . Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990; 58(2):281-95. View

10.

Ji B, Jamet P, Perani E, Bobin P, Grosset J . Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis. 1993; 168(1):188-90. DOI: 10.1093/infdis/168.1.188. View

11.

Ji B, Truffot-Pernot C, Lacroix C, Raviglione M, OBrien R, Olliaro P . Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993; 148(6 Pt 1):1541-6. DOI: 10.1164/ajrccm/148.6_Pt_1.1541. View

12.

Xiong J, Ji B, Perani E, Petinon C, Grosset J . Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis. 1994; 62(1):37-42. View

13.

Ji B, Perani E, Petinom C, Grosset J . Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother. 1996; 40(2):393-9. PMC: 163122. DOI: 10.1128/AAC.40.2.393. View

14.

Ji B, Jamet P, Perani E, Sow S, Lienhardt C, Petinon C . Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother. 1996; 40(9):2137-41. PMC: 163487. DOI: 10.1128/AAC.40.9.2137. View

15.

. Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. Indian J Lepr. 1997; 69(2):121-9. View

16.

Ji B, Sow S, Perani E, Lienhardt C, Diderot V, Grosset J . Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 1998; 42(5):1115-20. PMC: 105755. DOI: 10.1128/AAC.42.5.1115. View

17.

Goldstein E, Citron D, Gerardo S, Hudspeth M, Merriam C . Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens.... Antimicrob Agents Chemother. 1998; 42(5):1127-32. PMC: 105757. DOI: 10.1128/AAC.42.5.1127. View

18.

. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 1998; 874:1-43. View

19.

Hamilton-Miller J, Shah S . Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. J Antimicrob Chemother. 1998; 41(6):649-53. DOI: 10.1093/jac/41.6.649. View

20.

SHEPARD C, McRae D . A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968; 36(1):78-82. View